Navigation Links
Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
Date:9/1/2009

SCHAUMBURG, Ill., Sept. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of adenosine injection, USP, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia. Sagent will offer this latex-free, preservative-free adenosine product in 6 mg per 2 mL single-dose glass vials for intravenous use.

"This launch expands upon the full line of prefilled adenosine syringes we introduced in 2007, providing caregivers an array of adenosine delivery options in cardiac care settings," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Our 2 mL adenosine vial is the second product introduced from our collaboration with Strides Arcolab."

Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the U.S. market.

About Adenosine Injection, USP

Adenosine Injection, USP, is the generic equivalent of Astellas Pharma U.S., Inc.'s Adenocard(R), an antiarrhythmic commonly used in the treatment of paroxysmal supraventricular tachycardia, a rhythm disturbance of the heart, in critical care situations. Adenosine works by slowing the electrical conduction in the heart, slowing heart rate of normalizing heart rhythm.

Adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
2. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
3. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
4. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
5. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
6. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
7. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
8. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
9. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
10. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
11. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)... 2017  The China and Canada joint ... less water, energy and detergent, and features a powerful disinfection process. ... shoebox-sized washing machine that washes and sanitizes women,s panties or babies, ... ... and does not require an external water inlet. ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... The ... seminar to focus on current legislative activity and the latest regulatory concerns impacting ... p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are sure ... , “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
(Date:5/26/2017)... ... 26, 2017 , ... “When the Stars Lead Home”: a poignant story of ... author Laura Weigel Douglas, an avid reader who lives in the Pacific Northwest with ... like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the story of ... “Cactus Jack: Against All Odds” is the creation of published author, Walter Hubbard, a ... to Jack Carlisle’s third child Jane. Walter. Walter and Jane have three adult ...
Breaking Medicine News(10 mins):